Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Paclitaxel in combination with Pertuzumab, Trastuzumab, and Trastuzumab deruxtecan in patients with Invasive Breast Carcinoma.

Statements

Source and description

Enhertu (trastuzumab deruxtecan) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to fam-trastuzumab deruxtecan-nxki followed by a taxane, trastuzumab, and pertuzumab for the neoadjuvant treatment of adult patients with HER2-positive (immunohistochemistry 3+ or in situ hybridization positive) Stage II or III breast cancer as determined by an FDA-authorized test. This indication is based on DESTINY-Breast11 (NCT05113251), a randomized, open-label, multicenter study in which patients received fam-trastuzumab deruxtecan-nxki for 4 cycles followed by paclitaxel concurrent with trastuzumab and pertuzumab for 4 cycles.